{
  "title": "Vaccine Progress and What’s Next",
  "description": "Salveen Richter, lead analyst for the US Biotechnology sector in Goldman Sachs Research, talks about Pfizer’s clinical-trial results for its COVID-19 vaccine and the obstacles that still lie ahead for FDA approval and widespread distribution.",
  "pubDate": "Thu, 12 Nov 2020 17:47:45 -0000",
  "itunes:episodeType": "full",
  "itunes:author": "Goldman Sachs",
  "itunes:subtitle": "",
  "itunes:summary": "Salveen Richter, lead analyst for the US Biotechnology sector in Goldman Sachs Research, talks about Pfizer’s clinical-trial results for its COVID-19 vaccine and the obstacles that still lie ahead for FDA approval and widespread distribution.",
  "content:encoded": "<p>Salveen Richter, lead analyst for the US Biotechnology sector in Goldman Sachs Research, talks about Pfizer’s clinical-trial results for its COVID-19 vaccine and the obstacles that still lie ahead for FDA approval and widespread distribution.</p>",
  "itunes:duration": 596,
  "guid": "c091f9f2-250e-11eb-a9c8-070ab8fd6ef0",
  "enclosure": ""
}